Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

about

Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis.Molecular targets for radiation oncology in prostate cancer.

P2860

Q34734425-C1CC3D33-FE8A-4507-8A74-B9878F5BFADE Q36166840-769012F8-9E73-4FB0-95CB-AC67CDC4829A Q38014447-AD9AC7CB-BDE5-4CCF-A4EC-9B202F5636AE

P2860

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

Item

http://www.wikidata.org/entity/Q37193613

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

@en

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

@nl

type

Item

label

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

@en

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

@nl

prefLabel

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

@en

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

@nl

P1476

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

@en

P2093

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Donald A Podoloff

http://www.w3.org/2001/XMLSchema#string

Shi-Ming Tu

http://www.w3.org/2001/XMLSchema#string

Sue-Hwa Lin

http://www.w3.org/2001/XMLSchema#string

P2860

A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.

Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.

Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

P304

341-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20551894

http://www.w3.org/2001/XMLSchema#string

P932

4993042

http://www.w3.org/2001/XMLSchema#string

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

about

P2860

P2860

Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932